Premium
Combination chemotherapy and radiotherapy for Hodgkin's disease
Author(s) -
Rosenberg Saul A.,
Moore Melvin R.,
Bull Joan M.,
Jones Stephen E.,
Kaplan Henry S.
Publication year - 1972
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197212)30:6<1505::aid-cncr2820300614>3.0.co;2-l
Subject(s) - medicine , chemotherapy , radiation therapy , disease , combination chemotherapy , oncology , randomized controlled trial , surgery
A progress report is presented of a randomized clinical trial being conducted at Stanford University to test the value of combination chemotherapy following total lymphoid irradiation for patients with Hodgkin's disease. One hundred and thirteen previously untreated patients, with intermediate stages of disease, IB to IIIB , have been entered into the trial. The tolerance of patients to the prolonged aggressive treatment program is considered acceptable. With maximum follow‐up, approaching 4 years since onset of treatment, significant improvement in disease‐free survival has been observed, and overall survival is excellent. The factors which should make for a cautious interpretation of these early results are reviewed.